Literature DB >> 11025413

Expression of opioid receptors in osteoblast-like MG-63 cells, and effects of different opioid agonists on alkaline phosphatase and osteocalcin secretion by these cells.

J L Pérez-Castrillón1, J M Olmos, J J Gómez, A Barrallo, J A Riancho, L Perera, C Valero, J A Amado, J González-Macías.   

Abstract

We have previously shown that several stressful situations associated with tissue injury determine a decrease in serum osteocalcin concentration. Since reduced osteocalcin production is a marker of decreased osteoblastic activity, this finding could be related to the pathogenesis of osteoporosis secondary to some diseases. Endogenous opioids are involved in stress response. Proenkephalin-derived peptides have been shown to inhibit alkaline phosphatase activity, another marker of bone formation, in the murine cell line ROS-17/2.8. On the other hand, serum osteocalcin has been reported as being low in heroin abusers. We have therefore thought it of interest to study the presence of opioid receptors in the human osteoblast-like cell line MG-63, and to evaluate the effects of different opioid agonists on the secretion of alkaline phosphatase and osteocalcin by these cells. The presence of opioid receptors was studied by means of RT-PCR and immunohistochemistry. RT-PCR studies suggested the presence of specific mRNA for the three types of receptors, and immunohistochemistry clearly showed their occurrence. Osteocalcin synthesis was significantly inhibited by high concentrations of the mu agonists morphine and (D-Ala(2), N-MePhe(4),Gly(5)-ol)-enkephalin although no changes were seen with the delta agonist (D-Ala(2),D-leu(5))-enkephalin. Morphine-induced osteocalcin inhibition was abolished when osteoblastic cells were incubated simultaneously with naloxone, whereas it was potentiated when cells were preincubated with naloxone. None of the opioid agonists modified the secretion of alkaline phosphatase. In conclusion, human osteoblast-like cells MG-63 express the three types of opioid receptors. Endogenous opioids may be involved in the reduction of osteocalcin observed in stressful situations associated with tissue injury. Copyright 2000 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11025413     DOI: 10.1159/000054586

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  28 in total

Review 1.  Drug-induced osteoporosis: beyond glucocorticoids.

Authors:  Karine Briot; Christian Roux
Journal:  Curr Rheumatol Rep       Date:  2008-04       Impact factor: 4.592

Review 2.  Implications of analgesics use in osteoporotic-related pain treatment: focus on opioids.

Authors:  Renato Vellucci; Consalvo Mattia; Ludovica Celidonio; Rocco Domenico Mediati
Journal:  Clin Cases Miner Bone Metab       Date:  2016-10-05

3.  The association of opioid use with incident lower extremity fractures in spinal cord injury.

Authors:  Laura D Carbone; Amy S Chin; Todd A Lee; Stephen P Burns; Jelena N Svircev; Helen M Hoenig; Titilola Akhigbe; Frances M Weaver
Journal:  J Spinal Cord Med       Date:  2013-03       Impact factor: 1.985

Review 4.  Role of proopiomelanocortin-derived peptides and their receptors in the osteoarticular system: from basic to translational research.

Authors:  Markus Böhm; Susanne Grässel
Journal:  Endocr Rev       Date:  2012-06-26       Impact factor: 19.871

Review 5.  Engineering endomorphin drugs: state of the art.

Authors:  Lawrence H Lazarus; Yoshio Okada
Journal:  Expert Opin Ther Pat       Date:  2012-01-04       Impact factor: 6.674

Review 6.  Opioid-Induced Androgen Deficiency (OPIAD): Diagnosis, Management, and Literature Review.

Authors:  Timothy K O'Rourke; Matthew S Wosnitzer
Journal:  Curr Urol Rep       Date:  2016-10       Impact factor: 3.092

7.  Prospective study of bone mineral density changes in aging men with or at risk for HIV infection.

Authors:  Anjali Sharma; Peter L Flom; Jeremy Weedon; Robert S Klein
Journal:  AIDS       Date:  2010-09-24       Impact factor: 4.177

8.  Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results.

Authors:  Oyebimpe O Adesina; James G Gurney; Guolian Kang; Martha Villavicencio; Jason R Hodges; Wassim Chemaitilly; Sue C Kaste; Babette S Zemel; Jane S Hankins
Journal:  Blood Adv       Date:  2019-05-14

9.  Bisphosphonate treatment may reduce osteoporosis risk in female cancer patients with morphine use: a population-based nested case-control study.

Authors:  C W-S Lee; C-H Muo; J-A Liang; S-N Chang; Y-J Chang; C-H Kao
Journal:  Osteoporos Int       Date:  2013-03-08       Impact factor: 4.507

10.  Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent mu/delta-opioid receptor antagonist, regulates obese-related factors in mice.

Authors:  Ewa D Marczak; Yunden Jinsmaa; Page H Myers; Terry Blankenship; Ralph Wilson; Gianfranco Balboni; Severo Salvadori; Lawrence H Lazarus
Journal:  Eur J Pharmacol       Date:  2009-07-01       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.